196 related articles for article (PubMed ID: 12859220)
1. Cost evaluation of basiliximab treatment for renal transplant patients in Japan.
Hasegawa T; Imai H; Miki S
Pharmacoeconomics; 2003; 21(11):791-806. PubMed ID: 12859220
[TBL] [Abstract][Full Text] [Related]
2. Economic analysis of basiliximab in renal transplantation.
Keown PA; Balshaw R; Krueger H; Baladi JF
Transplantation; 2001 Jun; 71(11):1573-9. PubMed ID: 11435967
[TBL] [Abstract][Full Text] [Related]
3. A prospective economic evaluation of basiliximab (Simulect) therapy following renal transplantation.
Lorber MI; Fastenau J; Wilson D; DiCesare J; Hall ML
Clin Transplant; 2000 Oct; 14(5):479-85. PubMed ID: 11048993
[TBL] [Abstract][Full Text] [Related]
4. Meta-analysis of basiliximab for immunoprophylaxis in renal transplantation.
Keown P; Balshaw R; Khorasheh S; Chong M; Marra C; Kalo Z; Korn A
BioDrugs; 2003; 17(4):271-9. PubMed ID: 12899644
[TBL] [Abstract][Full Text] [Related]
5. Economic implications of the use of basiliximab in addition to triple immunosuppressive therapy in renal allograft recipients: a UK perspective.
Walters SJ; Whitfield M; Akehurst RL; Chilcott JB
Pharmacoeconomics; 2003; 21(2):129-38. PubMed ID: 12515574
[TBL] [Abstract][Full Text] [Related]
6. Randomised trial of basiliximab versus placebo for control of acute cellular rejection in renal allograft recipients. CHIB 201 International Study Group.
Nashan B; Moore R; Amlot P; Schmidt AG; Abeywickrama K; Soulillou JP
Lancet; 1997 Oct; 350(9086):1193-8. PubMed ID: 9652559
[TBL] [Abstract][Full Text] [Related]
7. Tacrolimus versus cyclosporin in renal transplantation in Italy: cost-minimisation and cost-effectiveness analyses.
Lazzaro C; McKechnie T; McKenna M
J Nephrol; 2002; 15(5):580-8. PubMed ID: 12455727
[TBL] [Abstract][Full Text] [Related]
8. The economics of basiliximab (Simulect) in preventing acute rejection in renal transplantation.
Chilcott JB; Holmes MW; Walters S; Akehurst RL; Nashan B
Transpl Int; 2002 Oct; 15(9-10):486-93. PubMed ID: 12389081
[TBL] [Abstract][Full Text] [Related]
9. Cost evaluation of basiliximab treatment for renal transplant patients in Japan.
Hasegawa T; Imai H; Miki S
Transplant Proc; 2003 Feb; 35(1):198-202. PubMed ID: 12591365
[No Abstract] [Full Text] [Related]
10. Basiliximab: a review of its use as induction therapy in renal transplantation.
Chapman TM; Keating GM
Drugs; 2003; 63(24):2803-35. PubMed ID: 14664658
[TBL] [Abstract][Full Text] [Related]
11. Effect of basiliximab on renal allograft rejection within 1 year after transplantation.
Lee BM; Oh CK; Jin SH; Kim JH; Kim SJ; Kim H; Shin GT
Transplant Proc; 2006 Sep; 38(7):2025-8. PubMed ID: 16979988
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and tolerability of interleukin-2 receptor blockade with basiliximab in pediatric renal transplant recipients.
Vester U; Kranz B; Testa G; Malagò M; Beelen D; Broelsch CE; Hoyer PF
Pediatr Transplant; 2001 Aug; 5(4):297-301. PubMed ID: 11472610
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of basiliximab in pediatric renal transplant patients receiving cyclosporine, mycophenolate mofetil, and steroids.
Offner G; Toenshoff B; Höcker B; Krauss M; Bulla M; Cochat P; Fehrenbach H; Fischer W; Foulard M; Hoppe B; Hoyer PF; Jungraithmayr TC; Klaus G; Latta K; Leichter H; Mihatsch MJ; Misselwitz J; Montoya C; Müller-Wiefel DE; Neuhaus TJ; Pape L; Querfeld U; Plank C; Schwarke D; Wygoda S; Zimmerhackl LB
Transplantation; 2008 Nov; 86(9):1241-8. PubMed ID: 19005406
[TBL] [Abstract][Full Text] [Related]
14. An economic model of 2-hour post-dose ciclosporin monitoring in renal transplantation.
Keown PA; Kiberd B; Balshaw R; Khorasheh S; Marra C; Belitsky P; Kalo Z
Pharmacoeconomics; 2004; 22(10):621-32. PubMed ID: 15244488
[TBL] [Abstract][Full Text] [Related]
15. Rabbit antithymocyte globulin versus basiliximab in renal transplantation.
Brennan DC; Daller JA; Lake KD; Cibrik D; Del Castillo D;
N Engl J Med; 2006 Nov; 355(19):1967-77. PubMed ID: 17093248
[TBL] [Abstract][Full Text] [Related]
16. Immunoprophylaxis with basiliximab, a chimeric anti-interleukin-2 receptor monoclonal antibody, in combination with azathioprine-containing triple therapy in liver transplant recipients.
Calmus Y; Scheele JR; Gonzalez-Pinto I; Jaurrieta EJ; Klar E; Pageaux GP; Scudamore CH; Cuervas-Mons V; Metselaar HJ; Prestele H; Girault D
Liver Transpl; 2002 Feb; 8(2):123-31. PubMed ID: 11862588
[TBL] [Abstract][Full Text] [Related]
17. A benefit-risk assessment of basiliximab in renal transplantation.
Boggi U; Danesi R; Vistoli F; Del Chiaro M; Signori S; Marchetti P; Del Tacca M; Mosca F
Drug Saf; 2004; 27(2):91-106. PubMed ID: 14717621
[TBL] [Abstract][Full Text] [Related]
18. Reduced acute rejection and superior 1-year renal allograft survival with basiliximab in patients with diabetes mellitus. The Global Simulect Study Group.
Thistlethwaite JR; Nashan B; Hall M; Chodoff L; Lin TH
Transplantation; 2000 Sep; 70(5):784-90. PubMed ID: 11003358
[TBL] [Abstract][Full Text] [Related]
19. Comparative study of the cellular pharmacodynamics of tacrolimus in renal transplant recipients treated with and without basiliximab.
Sugiyama K; Isogai K; Horisawa S; Toyama A; Satoh H; Saito K; Nakagawa Y; Tasaki M; Takahashi K; Hirano T
Cell Transplant; 2012; 21(2-3):565-70. PubMed ID: 22793066
[TBL] [Abstract][Full Text] [Related]
20. The cost effectiveness of tacrolimus versus microemulsified cyclosporin: a 10-year model of renal transplantation outcomes.
Orme ME; Jurewicz WA; Kumar N; McKechnie TL
Pharmacoeconomics; 2003; 21(17):1263-76. PubMed ID: 14986738
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
